The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.

The application relates to a method of assessing the risk of a patient for cervical pre-cancer or cancer, especially where there is no sign of a malignancy.

The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.

The present disclosure relates to a novel compound or a salt thereof, a composition for detecting cysteine, a fluorescent probe, and a composition for diagnosing cancer, which contain the same, a method for detecting cysteine, a method for providing information for diagnosing cancer, and a method for producing the novel compound. According to the present disclosure, there may be provided a method of synthesizing and purifying a fluorescent probe for cysteine detection and applying the same to diagnose cervical cancer by detecting cysteine in human urine.

The present invention is related to diagnostic tests or rapid detections of different types of cancer, especially cervical cancer and precancerous lesions. Especially, the invention relates to specific and useful protein biomarkers for the detection of said diseases, and to the methods for determination and detection of said biomarkers.

The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.

The invention provides antibodies that specifically bind to an epitope containing N-acetylglucosamine and specifically bind to an epitope comprising N-acetyl-galactosamine expressed by a cancer cell or an inflammatory cell. Further provided are methods for treating gastrointestinal diseases characterized by inflammatory cells in the intestines or colon in an individual by administering to the individual an antibody that specifically binds to an epitope containing N-acetylglucosamine and specifically binds to an epitope comprising N-acetyl-galactosamine.

Provided are biomarkers for predicting the prognosis of cervical cancer. In the case of using the biomarkers of the present disclosure, it is possible to select patients into a high-risk group, an intermediate-risk group, or a low-risk group, and thus, it is possible to provide tailored treatment for each patient according to prognosis prediction.

A fluorescence probe with mitochondrial targeting and two-photon property, its preparation method and application in detecting and tracking endogenous H.sub.2S in samples or living cells. The fluorescent probe is prepared by a four-step preparation method and demonstrates a UV-vis absorption increment .sub.ab=395 nm and 43 fold higher fluorescence intensity in the presence of H.sub.2S. The probe further demonstrates stability, selectivity for H.sub.2S over competing agents and sensitivity as low as 20 nm. A method of detecting endogenous H.sub.2S rapidly in the absence of any external stimulators is provided. Samples are contacted with the probe and the changes in fluorescence are monitored to detect H.sub.2S levels. The disclosed probe is non-toxic and suitable as a biomarker and therapeutic molecule in cancer and other diseases.

The invention relates to a device and a method for cancer detection and screening, based on analysis of Volatile Organic Compounds emitted by certain cancerous tumors. The device and method provide high sensitivity and specificity analyses. The sample to be analysed may be e.g. blood or blood plasma. In one aspect, the invention is directed towards detection of or screening for gynaecological cancers, e.g. ovarian cancer. Particularly, the device comprises the following parts: a sample holder for a fluid or solid body sample; an air inlet; a detector tube comprising 44-164 sensors; optionally an individual potentiometer connected to each sensor of the detector tube; an analogue to digital signal converter; four control cards; a computer-based program for the registration and statistical calculation of results; and an electricity source.